JP7681616B2 - アデノシン受容体拮抗薬化合物 - Google Patents

アデノシン受容体拮抗薬化合物 Download PDF

Info

Publication number
JP7681616B2
JP7681616B2 JP2022554968A JP2022554968A JP7681616B2 JP 7681616 B2 JP7681616 B2 JP 7681616B2 JP 2022554968 A JP2022554968 A JP 2022554968A JP 2022554968 A JP2022554968 A JP 2022554968A JP 7681616 B2 JP7681616 B2 JP 7681616B2
Authority
JP
Japan
Prior art keywords
substituted
compound
alkyl
amino
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022554968A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021099838A5 (https=
JP2023505915A5 (https=
JP2023505915A (ja
Inventor
ユン－スク リ
スン ウク クォン
キュン－スン キム
ジョン－グン キム
ジョン－ア キム
アン－ナ ムン
スン－ユン パク
ジュン－ス バン
ドン－クン ソン
ジュ－ユン ジュン
ソ－ジン リ
Original Assignee
イルドン ファーマシューティカル カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イルドン ファーマシューティカル カンパニー リミテッド filed Critical イルドン ファーマシューティカル カンパニー リミテッド
Publication of JP2023505915A publication Critical patent/JP2023505915A/ja
Publication of JPWO2021099838A5 publication Critical patent/JPWO2021099838A5/ja
Publication of JP2023505915A5 publication Critical patent/JP2023505915A5/ja
Priority to JP2025079712A priority Critical patent/JP2025120182A/ja
Application granted granted Critical
Publication of JP7681616B2 publication Critical patent/JP7681616B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
JP2022554968A 2019-11-19 2020-11-19 アデノシン受容体拮抗薬化合物 Active JP7681616B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025079712A JP2025120182A (ja) 2019-11-19 2025-05-12 アデノシン受容体拮抗薬化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020190149117A KR20210061202A (ko) 2019-11-19 2019-11-19 벤조나이트릴이 치환된 축합 피리미딘 유도체 및 그의 의약 용도
KR10-2019-0149117 2019-11-19
PCT/IB2020/000971 WO2021099838A1 (en) 2019-11-19 2020-11-19 Adenosine receptor antagonist compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025079712A Division JP2025120182A (ja) 2019-11-19 2025-05-12 アデノシン受容体拮抗薬化合物

Publications (4)

Publication Number Publication Date
JP2023505915A JP2023505915A (ja) 2023-02-13
JPWO2021099838A5 JPWO2021099838A5 (https=) 2024-12-04
JP2023505915A5 JP2023505915A5 (https=) 2024-12-04
JP7681616B2 true JP7681616B2 (ja) 2025-05-22

Family

ID=75980093

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022554968A Active JP7681616B2 (ja) 2019-11-19 2020-11-19 アデノシン受容体拮抗薬化合物
JP2025079712A Pending JP2025120182A (ja) 2019-11-19 2025-05-12 アデノシン受容体拮抗薬化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025079712A Pending JP2025120182A (ja) 2019-11-19 2025-05-12 アデノシン受容体拮抗薬化合物

Country Status (14)

Country Link
US (1) US12606564B2 (https=)
EP (1) EP4061817A4 (https=)
JP (2) JP7681616B2 (https=)
KR (3) KR20210061202A (https=)
CN (2) CN116425756B (https=)
AU (2) AU2020386189B2 (https=)
BR (2) BR122023020015A2 (https=)
CA (1) CA3158731A1 (https=)
CL (1) CL2022001307A1 (https=)
IL (1) IL293107A (https=)
MX (1) MX2022005976A (https=)
PH (1) PH12022551223A1 (https=)
TW (3) TWI851336B (https=)
WO (3) WO2021099832A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11806350B2 (en) 2020-11-19 2023-11-07 Ildong Pharmaceutical Co., Ltd. Prevention and/or treatment of CNS disorders
CN119173276A (zh) 2022-04-13 2024-12-20 吉利德科学公司 用于治疗表达Trop-2的癌症的组合疗法
TW202508599A (zh) * 2023-05-19 2025-03-01 南韓商尹諾衛醫藥有限公司 用於神經保護或治療α突觸核蛋白及/或神經發炎相關疾病的化合物
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
KR20250123663A (ko) 2024-02-08 2025-08-18 아이리드비엠에스 주식회사 Cxcr7 수용체 조절제 및 이의 용도

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004517874A (ja) 2001-01-10 2004-06-17 バーナリス リサーチ リミテッド プリン作動性レセプターアンタゴニストとしてのプリン誘導体
JP2004517861A (ja) 2001-01-10 2004-06-17 バーナリス リサーチ リミテッド プリン作動性レセプターアンタゴニストとしてのピラゾロ［３，４−ｄ］ピリミジン誘導体およびそれらの使用
WO2011050160A1 (en) 2009-10-22 2011-04-28 Biogen Idec Ma Inc. Pharmaceuticals, compositions and methods of making and using the same
JP2011525898A (ja) 2008-06-25 2011-09-29 バーナリス・（アール・アンド・ディ）・リミテッド プリン受容体アンタゴニストとしてのトリアゾロ［４，５−ｄ］ピリミジン誘導体およびその使用
WO2019086074A1 (de) 2017-10-31 2019-05-09 Helmholtz-Zentrum Dresden-Rossendorf E.V. 4-(furan-2-yl)-1h-pyrazolo[3,4-d]pyrimidin-6-amin-derivate und deren verwendung

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA971896B (en) * 1996-03-26 1998-09-07 Du Pont Merck Pharma Aryloxy-and arythio-fused pyridines and pyrimidines and derivatives
EP0901476A4 (en) * 1996-03-26 2001-08-16 Du Pont Pharm Co PYRIDINES AND PYRIMIDINES FUSION ARYLOXY AND ARYLTHIO AND DERIVATIVES THEREOF
PL337888A1 (en) * 1997-07-03 2000-09-11 Du Pont Pharm Co Imidazoprimidines and imidazopyridines for use in treating neurological disorders
US6841549B1 (en) * 1999-07-02 2005-01-11 Eisai Co., Ltd. Condensed imidazole compounds and a therapeutic agent for diabetes mellitus
GB0100624D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
DK1444233T3 (da) 2001-11-09 2011-10-17 Gilead Palo Alto Inc A2B-adenosinreceptorantagonister
EP1615926A1 (en) * 2003-04-21 2006-01-18 Ustav Organicke Chemie A Biochemie Akademie Ved Ceske Republiky (purin-6-yl) amino acid and production method thereof
WO2008153947A2 (en) * 2007-06-07 2008-12-18 Amgen Inc. Heterocyclic compounds as raf kinase modulators
CA2709784A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
EA201890730A1 (ru) 2015-09-16 2018-10-31 Локсо Онколоджи, Инк. Производные пиразолопиримидина в качестве ингибиторов btk для лечения злокачественного новообразования
BR122023024273A2 (pt) 2018-02-27 2024-02-20 Incyte Corporation Compostos imidazopirimidinas e triazolopirimidinas, seus usos, método para inibir uma atividade de um receptor de adenosina e composição farmacêutica dos mesmos
EP4061798B1 (en) 2019-11-19 2025-03-12 Clariant International Ltd Solvates of abscisic acid and liquid compositions containing abscisic acid
MX2022005914A (es) 2019-11-19 2022-08-04 Modag Gmbh Compuestos novedosos para el diagnostico, tratamiento y prevencion de enfermedades asociadas con la agregacion de alfa-sinucleina.
US11806350B2 (en) * 2020-11-19 2023-11-07 Ildong Pharmaceutical Co., Ltd. Prevention and/or treatment of CNS disorders

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004517874A (ja) 2001-01-10 2004-06-17 バーナリス リサーチ リミテッド プリン作動性レセプターアンタゴニストとしてのプリン誘導体
JP2004517861A (ja) 2001-01-10 2004-06-17 バーナリス リサーチ リミテッド プリン作動性レセプターアンタゴニストとしてのピラゾロ［３，４−ｄ］ピリミジン誘導体およびそれらの使用
JP2011525898A (ja) 2008-06-25 2011-09-29 バーナリス・（アール・アンド・ディ）・リミテッド プリン受容体アンタゴニストとしてのトリアゾロ［４，５−ｄ］ピリミジン誘導体およびその使用
WO2011050160A1 (en) 2009-10-22 2011-04-28 Biogen Idec Ma Inc. Pharmaceuticals, compositions and methods of making and using the same
WO2019086074A1 (de) 2017-10-31 2019-05-09 Helmholtz-Zentrum Dresden-Rossendorf E.V. 4-(furan-2-yl)-1h-pyrazolo[3,4-d]pyrimidin-6-amin-derivate und deren verwendung

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Langmead, Christopher J. et al.，Identification of Novel Adenosine A2A Receptor Antagonists by Virtual Screening，Journal of Medicinal Chemistry，2012年，55(5)，1904-1909

Also Published As

Publication number Publication date
EP4061817A4 (en) 2023-11-01
TW202342481A (zh) 2023-11-01
KR20240148969A (ko) 2024-10-11
TWI851336B (zh) 2024-08-01
IL293107A (en) 2022-07-01
CN114829363B (zh) 2024-10-01
KR102752564B1 (ko) 2025-01-14
EP4061817A1 (en) 2022-09-28
WO2021099838A1 (en) 2021-05-27
WO2021099832A2 (en) 2021-05-27
KR102749480B1 (ko) 2025-01-07
CA3158731A1 (en) 2021-05-27
JP2023505915A (ja) 2023-02-13
MX2022005976A (es) 2022-08-18
TW202132304A (zh) 2021-09-01
CN114829363A (zh) 2022-07-29
AU2023202886A1 (en) 2023-05-25
WO2021099832A3 (en) 2021-07-01
CN116425756B (zh) 2025-05-13
BR122023020015A2 (pt) 2024-02-27
PH12022551223A1 (en) 2023-07-17
WO2021099838A9 (en) 2021-09-30
AU2020386189A1 (en) 2022-06-02
WO2021099838A8 (en) 2021-08-12
CL2022001307A1 (es) 2023-03-03
KR20220104760A (ko) 2022-07-26
WO2021099837A1 (en) 2021-05-27
TWI850492B (zh) 2024-08-01
TW202132305A (zh) 2021-09-01
CN116425756A (zh) 2023-07-14
US20230159534A1 (en) 2023-05-25
JP2025120182A (ja) 2025-08-15
US12606564B2 (en) 2026-04-21
AU2020386189B2 (en) 2024-05-16
KR20210061202A (ko) 2021-05-27
BR112022009487A2 (pt) 2023-02-23
AU2023202886B2 (en) 2024-11-14

Similar Documents

Publication Publication Date Title
JP7681616B2 (ja) アデノシン受容体拮抗薬化合物
JP7672451B2 (ja) Ｒｈｏ－関連プロテインキナーゼ阻害剤、それを含む医薬組成物並びにその調製方法及び使用
AU2022263410B2 (en) Carboxy-benzimidazole glp-1r modulating compounds
KR101541086B1 (ko) 피롤로피리미딘 화합물 및 그 용도
JP2019524676A (ja) 新規な４−アミノピラゾロ［３，４−ｄ］ピリミジニルアザビシクロ誘導体およびこれを含む薬学組成物
TW201639831A (zh) 作為抗癌藥物的取代的２－氫－吡唑衍生物
KR20130116358A (ko) Pi3 키나아제 억제제로서 헤테로사이클릭 화합물
AU2018350980A1 (en) Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-y gamma inhibitors
TW202237609A (zh) Cns病症之預防及/或治療
JP2026500291A (ja) Ｔｐ５３－ｙ２２０ｃ変異体をターゲティングするための化合物及び組成物
TW202330519A (zh) 作為ｔａｍ抑制劑的吡唑并吡啶化合物
JP2025504495A (ja) Ｒａｓシグナル伝達の調節因子としての縮合複素環式化合物
KR20190085112A (ko) Gsk-3 억제제
EA050210B1 (ru) Соединения-антагонисты аденозиновых рецепторов
EA051725B1 (ru) Соединения-антагонисты аденозиновых рецепторов
HK40077081A (en) Adenosine receptor antagonist compounds
HK40097385A (zh) 腺苷受体拮抗剂化合物及其应用
WO2015016195A1 (ja) Ｗｎｔシグナル阻害剤
CN120774920A (zh) PI3Kδ-mTOR双靶点抑制剂及其制备方法和应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230927

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230927

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240815

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241126

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20241126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250116

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250410

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250512

R150 Certificate of patent or registration of utility model

Ref document number: 7681616

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150